Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Apatinibmesylat kombineret med IT-regimen til behandling af tilbagevendende eller refraktær pædiatrisk neuroblastom

5. november 2026 opdateret af: Yizhuo Zhang, Sun Yat-sen University

Apatinibmesylat kombineret med IT-regimen til behandling af recidiverende eller refraktær pædiatrisk neuroblastom: Multicenter, enkeltarm, fase II klinisk undersøgelse.

The survival rate of recurrent and refractory neuroblastoma is low and the prognosis is poor. Apatinib mesylate is a highly selective small-molecule vasoendothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor. Apatinib mesylate has been shown to be safe and effective in recurrent or refractory pediatric neuroblastoma in Sun Yat-sen University Cancer Center. Apatinib mesylate combined with IT regimen is expected to further improve the efficacy and survival rate of recurrent or refractory neuroblastoma.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

The enrolled patients diagnosed with recurrent or refractory neuroblastoma received apatinib combined with IT regimen chemotherapy, including phase I and phase II stage. During the Phase I stage, apatinib was administered using a 3+3 dose escalation design with three dose cohorts. The IT regimen was maintained at fixed doses, with patients receiving up to 8 cycles of chemotherapy. The recommended Phase II dose (RP2D) was determined from the Phase I dose-escalation phase.

In the Phase II stage, the study included an apatinib combination therapy phase and an apatinib maintenance therapy phase. During the combination therapy phase, apatinib was administered at the RP2D in combination with the IT regimen (at fixed doses) for up to 8 cycles. In the maintenance therapy phase, apatinib was administered orally as a single agent at the RP2D until disease progression or intolerable toxicity occurred.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

111

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Guangdong
      • Guangzhou, Guangdong, Kina
        • Sun Yat-sen University Cancer Center
      • Guangzhou, Guangdong, Kina
        • The First Affiliated Hospital of Guangdong Pharmaceutical University
      • Guangzhou, Guangdong, Kina
        • The Fifth Affiliated Hospital of Guangzhou Medical University
    • Hubei
      • Wuhan, Hubei, Kina
        • Wuhan Children's Hospital
    • Shandong
      • Jinan, Shandong, Kina
        • Jinan Children's Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

2 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥2 years (for patients enrolled in Phase 1, age <18 years); no gender restriction.
  2. Karnofsky Performance Status (KPS) score ≥50 for patients aged ≥16 years, or Lansky Performance Status (LPS) score ≥50 for patients aged <16 years (see Appendix 1).
  3. Estimated life expectancy of at least 12 weeks.
  4. Histologically confirmed diagnosis of neuroblastoma meeting clinical diagnostic criteria.
  5. Disease progression, recurrence, or treatment resistance (failure to achieve CR or PR following the most recent therapy) after first-line treatment.
  6. Measurable or evaluable disease (per INRC criteria; see Appendix 3; target lesions must not have received prior local treatment such as radiotherapy or cryotherapy).
  7. Complete recovery from all acute toxic effects of prior anticancer chemotherapy.
  8. Myelosuppressive chemotherapy: at least 21 days since the last myelosuppressive chemotherapy regimen (or 42 days if nitrosoureas were administered).
  9. Investigational agents or anticancer therapies other than chemotherapy: must not have been administered within 28 days prior to the planned initiation of the AIT regimen. Complete recovery from any clinically significant toxicity associated with such therapy must be confirmed.
  10. Hematopoietic growth factors: at least 14 days since the last administration of long-acting growth factors, or at least 3 days since the last administration of short-acting growth factors.
  11. Immunotherapy: at least 42 days since completion of any type of immunotherapy (excluding corticosteroids), such as immune checkpoint inhibitors or tumor vaccines.
  12. Radiotherapy (XRT): at least 14 days since localized palliative XRT (small-field irradiation); for other substantial bone marrow irradiation, including prior ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy, a minimum interval of 42 days is required.
  13. Stem cell infusion without total body irradiation: no evidence of active graft-versus-host disease, and at least 56 days since transplantation or stem cell infusion.
  14. Laboratory tests during the screening period must meet the following criteria:

(1)Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L (≥1.0 × 10⁹/L if bone marrow involvement is present) (2)Platelet count (PLT) ≥75 × 10⁹/L (≥50 × 10⁹/L if bone marrow involvement is present) (3)Total bilirubin ≤1.5 × upper limit of normal (ULN) (4)Serum creatinine ≤1.5 × ULN (5)Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤3 × ULN (may be ≤5 × ULN in the presence of liver metastases) 15.Ability to comply with outpatient treatment, laboratory monitoring, and required clinical visits during study participation.

16.Parents/legal guardians of pediatric or adolescent subjects must be capable of understanding, agreeing to, and signing the informed consent form (ICF) and applicable pediatric assent forms prior to the initiation of any protocol-related procedures. With parental/guardian consent, subjects must be capable of expressing assent (where applicable).

EXCLUSION CRITERIA:

Patients meeting any of the following criteria are ineligible for inclusion in this study:

  1. Symptomatic brain metastases (patients with brain metastases who have completed treatment within 21 days prior to enrolment and have stable symptoms may be enrolled, provided that cranial magnetic resonance imaging [MRI], computed tomography [CT], or venography confirms the absence of cerebral haemorrhage).
  2. Imaging (CT or MRI) demonstrating that the tumour lesion is located ≤5 mm from a major blood vessel, or that the tumour invades a local major blood vessel.
  3. Hypertension currently requiring treatment with two or more antihypertensive medications.
  4. Prior or concurrent clinically significant cardiovascular disease, including congenital heart disease, pericardial disease, history of heart failure, myocardial infarction, coronary artery disease, valvular heart disease, cardiomyopathy, or arrhythmias (including persistent atrial fibrillation, complete left bundle branch block, or frequent premature ventricular contractions); corrected QT interval (QTc) >480 ms; New York Heart Association (NYHA) Class III-IV cardiac dysfunction for patients aged >3 years or corresponding criteria for infantile cardiac function for patients aged ≤3 years (see Appendix 2); or echocardiography demonstrating left ventricular ejection fraction (LVEF) <50%.
  5. History of or concurrent interstitial lung disease.
  6. Abnormal coagulation function (international normalised ratio [INR] >1.5, prothrombin time [PT] >ULN + 4 seconds, or activated partial thromboplastin time [APTT] >1.5 × ULN), bleeding tendency, or ongoing thrombolytic or anticoagulant therapy.
  7. Haemoptysis of ≥2 teaspoons daily prior to enrolment.
  8. Clinically significant bleeding symptoms or clear bleeding tendency within the preceding 3 months, such as gastrointestinal bleeding, haemorrhagic haemorrhoids, haemorrhagic gastric ulcer, baseline faecal occult blood ≥++, or vasculitis.
  9. Arterial or venous thromboembolic events within 12 months prior to enrolment, including cerebrovascular accident (transient ischaemic attack, cerebral haemorrhage, or cerebral infarction), deep vein thrombosis, or pulmonary embolism.
  10. Known hereditary or acquired bleeding or thrombotic tendency (e.g., haemophilia, coagulation disorders, thrombocytopenia, or hypersplenism).
  11. Chronic non-healing wounds or fractures (excluding pathological fractures caused by tumours).
  12. Major surgical procedure, severe traumatic injury, fracture, or ulcer within 4 weeks prior to enrolment.
  13. Factors that significantly affect absorption of oral medications, such as inability to swallow, chronic diarrhoea, or intestinal obstruction.
  14. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to enrolment.
  15. Urinalysis showing urinary protein ≥++, with confirmed 24-hour urinary protein excretion ≥1.0 g.
  16. Symptomatic serous effusion requiring intervention (including pleural effusion, ascites, and pericardial effusion). Note: Patients with asymptomatic serous effusion may be enrolled. Patients with symptomatic serous effusion who have received active symptomatic management (anticancer drugs are not permitted for the treatment of serous effusion) and are deemed eligible by the investigator may be enrolled.
  17. Active infection requiring antimicrobial therapy (e.g., antibacterial or antiviral agents, excluding anti-hepatitis B virus [HBV] therapy for chronic hepatitis B or antifungal therapy).
  18. History of psychotropic substance abuse with inability to abstain, or presence of a psychiatric disorder.
  19. Participation in another clinical trial involving antitumour agents within 4 weeks prior to enrolment.
  20. Prior or concurrent untreated malignancy, excluding cured basal cell carcinoma of the skin, cervical carcinoma in situ, or superficial bladder cancer.
  21. Use of medications or foods known to be potent cytochrome P450 3A4 (CYP3A4) inhibitors within 7 days prior to the first dose, including but not limited to: atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, and voriconazole.
  22. Use of medications known to be potent CYP3A4 inducers within 12 days prior to the first dose, including but not limited to: carbamazepine, phenobarbital, phenytoin, rifabutin, and rifampicin.
  23. Any other condition that, in the investigator's judgement, may affect the conduct of the clinical study or interpretation of results.
  24. Virological tests during the screening period meeting any of the following criteria:

(1)Hepatitis B surface antigen (HBsAg)-positive with HBV DNA levels exceeding the ULN (2)Anti-hepatitis C virus (HCV) antibody-positive and HCV ribonucleic acid (RNA)-positive Human immunodeficiency virus (HIV)-positive

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: The first dose level

The first dose level of apatinib combined with fixed-dose 5-day courses of irinotecan (50 mg/m²/dose infused IV 90 min) plus temozolomide (150 mg/m²/dose infused IV 90 min) for up to 8 courses.

In the Phase I stage, apatinib was administered using a 3+3 dose escalation design with three dose cohorts. The IT regimen was maintained at fixed doses, with patients receiving up to 8 cycles of chemotherapy. The recommended Phase II dose (RP2D) was determined from the Phase I dose-escalation phase.

In the Phase II stage, the study included an apatinib combination therapy phase and an apatinib maintenance therapy phase. During the combination therapy phase, apatinib was administered at the RP2D in combination with the IT regimen (at fixed doses) for up to 8 cycles. In the maintenance therapy phase, apatinib was administered orally as a single agent at the RP2D until disease progression or intolerable toxicity occurred.

Andre navne:
  • Irinotecan
  • temozolomid
Eksperimentel: The second dose level

The second dose level of apatinib combined with fixed-dose 5-day courses of irinotecan (50 mg/m²/dose infused IV 90 min) plus temozolomide (150 mg/m²/dose infused IV 90 min) for up to 8 courses.

In the Phase I stage, apatinib was administered using a 3+3 dose escalation design with three dose cohorts. The IT regimen was maintained at fixed doses, with patients receiving up to 8 cycles of chemotherapy. The recommended Phase II dose (RP2D) was determined from the Phase I dose-escalation phase.

In the Phase II stage, the study included an apatinib combination therapy phase and an apatinib maintenance therapy phase. During the combination therapy phase, apatinib was administered at the RP2D in combination with the IT regimen (at fixed doses) for up to 8 cycles. In the maintenance therapy phase, apatinib was administered orally as a single agent at the RP2D until disease progression or intolerable toxicity occurred.

Andre navne:
  • Irinotecan
  • temozolomid
Eksperimentel: The third dose level

The third dose level of apatinib combined with fixed-dose 5-day courses of irinotecan (50 mg/m²/dose infused IV 90 min) plus temozolomide (150 mg/m²/dose infused IV 90 min) for up to 8 courses.

In the Phase I stage, apatinib was administered using a 3+3 dose escalation design with three dose cohorts. The IT regimen was maintained at fixed doses, with patients receiving up to 8 cycles of chemotherapy. The recommended Phase II dose (RP2D) was determined from the Phase I dose-escalation phase.

In the Phase II stage, the study included an apatinib combination therapy phase and an apatinib maintenance therapy phase. During the combination therapy phase, apatinib was administered at the RP2D in combination with the IT regimen (at fixed doses) for up to 8 cycles. In the maintenance therapy phase, apatinib was administered orally as a single agent at the RP2D until disease progression or intolerable toxicity occurred.

Andre navne:
  • Irinotecan
  • temozolomid
Eksperimentel: Phase 2: The RPIID group

Based on the Phase I stage of apatinib, the recommended phase II dose was administered in combination with the IT regimen every three weeks for up to 8 cycles, followed by maintenance therapy with apatinib until tumor progression recurrence or unacceptable toxicity.

In the Phase I stage, apatinib was administered using a 3+3 dose escalation design with three dose cohorts. The IT regimen was maintained at fixed doses, with patients receiving up to 8 cycles of chemotherapy. The recommended Phase II dose (RP2D) was determined from the Phase I dose-escalation phase.

In the Phase II stage, the study included an apatinib combination therapy phase and an apatinib maintenance therapy phase. During the combination therapy phase, apatinib was administered at the RP2D in combination with the IT regimen (at fixed doses) for up to 8 cycles. In the maintenance therapy phase, apatinib was administered orally as a single agent at the RP2D until disease progression or intolerable toxicity occurred.

Andre navne:
  • Irinotecan
  • temozolomid

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Best objective response rate (Phase 2)
Tidsramme: Up to 8 cycles of combination therapy (approximately 6 months)

Proportion of patients with a best overall response of complete response (CR) or partial response (PR) according to the revised International Neuroblastoma Response Criteria, assessed by the investigator in phase 2 patients treated at the recommended phase 2 dose (RP2D).

Up to 8 cycles of combination therapy (approximately 6 months)
Incidence of dose-limiting toxicity (Phase 1)
Tidsramme: First 21-day cycle after the first apatinib dose

Proportion of DLT-evaluable patients experiencing at least one dose-limiting toxicity during the first 21-day cycle, defined as grade ≥3 febrile neutropenia; grade 4 neutropenia persisting >7 days despite G-CSF; grade 4 thrombocytopenia or grade 3 thrombocytopenia with clinically significant bleeding; grade ≥4 anaemia; grade ≥3 non-haematological toxicity not resolving to grade ≤2 within 7 days despite optimal supportive care; or any adverse event requiring treatment interruption >7 days or dose reduction.

First 21-day cycle after the first apatinib dose
Maximum tolerated dose and recommended phase 2 dose (Phase 1)
Tidsramme: At completion of phase 1 dose escalation

Maximum tolerated dose (MTD) determined by the 3+3 dose-escalation design, and recommended phase 2 dose (RP2D) determined from an integrated review of dose-limiting toxicities, grade ≥3 adverse events, serious adverse events, dose interruptions and reductions, tolerability, treatment compliance and pharmacokinetic exposure.

At completion of phase 1 dose escalation

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression-free survival
Tidsramme: Up to 60 months

Time from enrollment to first documented disease progression or death from any cause, whichever occurs first.

Up to 60 months
Overall survival
Tidsramme: Up to 60 months

Time from enrollment to death from any cause.

Up to 60 months
duration of response(DOR)
Tidsramme: Up to 60 months

Time from the first documented confirmed complete or partial response to first documented disease progression or death from any cause, whichever occurs first, among responders.

Up to 60 months
Disease control rate (DCR)
Tidsramme: Up to 8 cycles of combination therapy (approximately 6 months)

Proportion of patients with a best overall response of complete response, partial response, minor response, or stable disease lasting at least 8 weeks.

Up to 8 cycles of combination therapy (approximately 6 months)
Time to response
Tidsramme: Up to 60 months

Time from the first study treatment to the first documented confirmed complete or partial response among responders.

Up to 60 months
Safety and tolerability
Tidsramme: From first dose until 30 days after the last dose (up to 60 months)

Incidence and severity of adverse events and serious adverse events, and the number and reason for dose interruptions and dose reductions, graded according to NCI-CTCAE version 5.0.

From first dose until 30 days after the last dose (up to 60 months)
Pharmacokinetic parameters of apatinib (Phase 1)
Tidsramme: First 48 hours after the first apatinib dose

Cmax, Tmax, AUC0-t, AUC0-inf, terminal half-life, mean residence time, clearance and apparent volume of distribution of apatinib after the first dose, analysed by non-compartmental methods.

First 48 hours after the first apatinib dose
Objective response rate (Phase 1)
Tidsramme: Up to 8 cycles of combination therapy (approximately 6 months)

Proportion of phase 1 patients achieving a complete or partial response.

Up to 8 cycles of combination therapy (approximately 6 months)

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Genomic biomarkers associated with antitumor activity (exploratory)
Tidsramme: Baseline tumour tissue; association analyses through data cutoff (up to 60 months)

Association between tumour genomic alterations, including pathway-level alteration frequencies and tumour mutational burden assessed by whole-exome sequencing of paired tumour and germline samples, and antitumor activity (objective response, disease control, progression-free survival and overall survival) in the biomarker-evaluable population.

Baseline tumour tissue; association analyses through data cutoff (up to 60 months)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Yizhuo Zhang, Sun Yat-Sen University Cancer Center

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

26. august 2021

Primær færdiggørelse (Faktiske)

4. februar 2026

Studieafslutning (Faktiske)

4. februar 2026

Datoer for studieregistrering

Først indsendt

22. august 2021

Først indsendt, der opfyldte QC-kriterier

24. august 2021

Først opslået (Faktiske)

30. august 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner